Skip to main content
SpringerLink
Log in

Sodium Fluoride Imaging in Oncology

  • Chapter
  • First Online:
Book cover Sodium Fluoride PET/CT in Clinical Use

Part of the book series: Clinicians’ Guides to Radionuclide Hybrid Imaging ((PET/CT))

Abstract

18F-NaF PET/CT has established its place in the oncologic clinical routine. It has essential role in initial staging, detection of suspected first osseous metastasis, suspected progression of osseous metastasis, or treatment monitoring in many types of cancer, such as prostate, lung, and breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Segall G, Delbeke D, Stabin MG, et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med. 2010;51:1813–20.

    Article  PubMed  Google Scholar 

  2. Gareen IF, Hillner BE, Hanna L, et al. Hospice admission and survival after 18F-fluoride PET performed for evaluation of osseous metastatic disease in the national oncologic PET registry. J Nucl Med. 2018;59:427–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Oyen W, Sundram F, Haug AR, et al. Radium-223 dichloride (Ra-223) for the treatment of metastatic castration-resistant prostate cancer: optimizing clinical practice in nuclear medicine centers. J Oncopathol. 2015;3:1–25.

    Article  Google Scholar 

  4. Sorto G, Gallichio R, Pellegrino T, et al. Impact of 18F-fluoride PET/CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP. Nucl Med Biol. 2013;40:518–23.

    Article  Google Scholar 

  5. Even-Sapir E, Metser U, Mishani E, et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy; single- and multi-field-of-view SPECT; 18F-fluoride PET; and 18Ffluoride PET/CT. J Nucl Med. 2006;47:287–97.

    PubMed  Google Scholar 

  6. Kairemo K, Milton DR, Etchebehere E, et al. Final outcome of 223Ra-therapy and the role of 18F-fluoride-PET in response evaluation in metastatic castration-resistant prostate cancer–a single institution experience. Curr Radiopharm. 2018;11:152–7.

    Google Scholar 

  7. Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM. Prognostic factors in patients treated with 223Ra: the role of skeletal tumor turden on baseline 18Ffluoride PET/CT in predicting overall survival. J Nucl Med. 2015;56:1177–84.

    Article  CAS  PubMed  Google Scholar 

  8. von Eyben FE, Kairemo K, Kiljunen T, Joensuu T. Planning of external beam radiotherapy for prostate cancer guided by PET/CT. Curr Radiopharm. 2015;8:19–31.

    Article  Google Scholar 

  9. Hillner BE, Siegel BA, Hanna L, Duan F, Shields AF, Coleman RE. Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the national oncologic PET registry. J Nucl Med. 2014;55:574–81.

    Article  CAS  PubMed  Google Scholar 

  10. Langsteger W, Balogova S, Huchet V, et al. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Q J Nucl Med Mol Imaging. 2011;55:448–57.

    CAS  PubMed  Google Scholar 

  11. Scher HI, Sawyers CL. Biology of progressive, castration resistant prostate cancer: directed therapies targeting the androgen receptor signaling axis. J Clin Oncol. 2005;23:8253–61.

    Article  CAS  PubMed  Google Scholar 

  12. Kairemo K, Joensuu T. Radium-223-dichloride in castration resistant metastatic prostate cancer-preliminary results of the response evaluation using F-18-fluoride PET/CT. Diagnostics (Basel). 2015;5:413–27.

    Article  CAS  Google Scholar 

  13. Etchebehere E, Brito AE, Rezaee A, et al. Therapy assessment of bone metastatic disease in the era of 223radium. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):84–96.

    Article  CAS  PubMed  Google Scholar 

  14. Taube T, Elomaa I, Blomqvist C, Beneton MN, Kanis JA. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone. 1994;15:161–6.

    Article  CAS  PubMed  Google Scholar 

  15. WAM B, van der Zant FM, Wondergem M, Knol RJJ. Accuracy of 18F-NaF PET/CT in bone metastasis detection and its effect on patient management in patients with breast carcinoma. Nucl Med Commun. 2018;39(4):325–33.

    Google Scholar 

  16. Brito AE, Santos A, Sasse AD, et al. 18F-Fluoride PET/CT tumor burden quantification predicts survival in breast cancer. Oncotarget. 2017;8(22):36001–11.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Azad G, Siddique MM, Taylor B, et al. Does measurement of 18F-fluoride metabolic flux improve response assessment of breast cancer bone metastases compared with standardised uptake values in 18F-fluoride PET/CT? J Nucl Med. 2019;60:322. https://doi.org/10.2967/jnumed.118.208710.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Peterson LM, O’Sullivan J, Wu QV, et al. Prospective study of serial 18F-FDG PET and 18F-fluoride (18F-NaF) PET to predict time to skeletal related events, time-to-progression, and survival in patients with bone-dominant metastatic breast cancer. J Nucl Med. 2018;59:1823. https://doi.org/10.2967/jnumed.118.211102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Rao L, Zong Z, Chen Z, et al. 18F-labeled NaF PET/CT in detection of bone metastases in patients with preoperative lung cancer. Medicine (Baltimore). 2016;95:e3490.

    Article  CAS  Google Scholar 

  20. Lee H, Lee WW, Park SY, Kim SE. F-18 sodium fluoride positron emission tomography/computed tomography for detection of thyroid cancer bone metastasis compared with bone scintigraphy. Korean J Radiol. 2016;17:281–8. https://doi.org/10.3348/kjr.2016.17.2.281.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Ota N, Kato K, Iwano S, et al. Comparison of 18F-fluoride PET/CT, 18F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study. Br J Radiol. 2014;87:20130444.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Schirrmeister H, Buck A, Guhlmann A, Reske SN. Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography. Thyroid. 2001;11:677–83.

    Article  CAS  PubMed  Google Scholar 

  23. Gerety EL, Lawrence EM, Wason J, et al. Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design. Ann Oncol. 2015;26:2113–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Sharma P, Karunanithi S, Chakraborty PS, et al. 18F-fluoride PET/CT for detection of bone metastasis in patients with renal cell carcinoma: a pilot study. Nucl Med Commun. 2014;35:1247–53.

    Article  CAS  PubMed  Google Scholar 

  25. Duarte PS, de Castroneves LA, Sado HN, et al. Bone and calcified soft tissue metastases of medullary thyroid carcinoma better characterized on 18F-fluoride PET/CT than on 68Ga-Dotatate PET/CT. Nucl Med Mol Imaging. 2018;52:318–23. https://doi.org/10.1007/s13139-018-0527-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Duarte PS, Marin JFG, Carvalho D, et al. Brain metastasis of medullary thyroid carcinoma without macroscopic calcification detected first on 68Ga-Dotatate and then on 18F-fluoride PET/CT. Clin Nucl Med. 2018;43:623–4.

    Article  PubMed  Google Scholar 

  27. do Vale RH, Marin JF, Duarte PS, Sapienza MT, Buchpiguel CA. Visualization of lymph nodal and hepatic metastases of medullary thyroid carcinoma on 18F-fluoride PET/CT. Clin Nucl Med. 2015;40:895–6.

    Article  PubMed  Google Scholar 

  28. Basu S, Ranade R, Thapa P. 177Lu-DOTATATE versus 177Lu-EDTMP versus cocktail/sequential therapy in bone-confined painful metastatic disease in medullary carcinoma of the thyroid and neuroendocrine tumour: can semiquantitative comparison of 68Ga-DOTATATE and 18F-fluoride PET/CT aid in personalized treatment decision making in selecting the best therapeutic option? Nucl Med Commun. 2016;37:100–2.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine and Molecular Radiotherapy, Docrates Cancer Center, Helsinki, Finland

    Kalevi Kairemo

  2. Department of Nuclear Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Kalevi Kairemo & Homer A. Macapinlac

Authors
  1. Kalevi Kairemo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Homer A. Macapinlac
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Kalevi Kairemo

  2. Department of Nuclear Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Homer A. Macapinlac

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kairemo, K., Macapinlac, H.A. (2020). Sodium Fluoride Imaging in Oncology. In: Kairemo, K., Macapinlac, H.A. (eds) Sodium Fluoride PET/CT in Clinical Use. Clinicians’ Guides to Radionuclide Hybrid Imaging(). Springer, Cham. https://doi.org/10.1007/978-3-030-23577-2_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-23577-2_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-23576-5

  • Online ISBN: 978-3-030-23577-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation